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ABSTRACT
Chemotherapy-induced diarrhea (CID) is a common
side effect of cancer treatment and can cause signifi-
cant morbidity and mortality. Diarrhea is frequently
severe enough to require a dose reduction of, a delay
in, or a discontinuation of chemotherapy. Diarrhea-
associated mortality has been reported to be as high
as 3.5% in clinical trials of irinotecan and bolus
5-fluorouracil in colorectal cancer. The frequency of
CID and its impact on patient management are fre-
quently under-recognized in clinical practice.
A Canadian working group, consisting of medi-
cal oncologists and an oncology pharmacist, was
formed in 2001 to review the optimal approach to
managing  CID and to identify and implement new areas
of research. The recommendations that follow are the
result of the group’s work.
Acute medical management of CID includes
loperamide or diphenoxylate as first-line agents. Sub-
cutaneous octreotide is recommended for intractable
grade 2 diarrhea and may be considered for grade 1
CID that does not resolve with high-dose loperamide.
Hospitalization is recommended for patients with
grades 3 and 4 CID; in-hospital care includes rehy-
dration, antibiotic therapy, and octreotide.
A chemotherapy dose reduction is generally ad-
vised for patients who have experienced grade 3 or
4 diarrhea in a previous chemotherapy cycle. If a
dose reduction is not desired, prophylaxis with in-
tramuscular long-acting release octreotide may be
considered.
The foregoing recommendations are based on ex-
pert opinion and require validation in prospective
clinical trials.
KEY WORDS
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1. INTRODUCTION
Diarrhea is a common side effect of chemotherapy,
notably those regimens that include bolus fluorouracil
(5-FU) and irinotecan. The incidence of all grades of
diarrhea during chemotherapy has been reported to be
as high as 82%, with up to one third of patients expe-
riencing severe (grade 3 or 4) diarrhea (Table I) 2,18.
The frequency of chemotherapy-induced diarrhea
(CID) is well-established, but its impact on patient
morbidity and mortality may be under-recognized.
Chemotherapy-induced diarrhea can be severe
enough to result in fluid and electrolyte losses, which
can cause potentially life-threatening dehydration,
electrolyte imbalances, and renal insufficiency; in
nutritional deficiencies from alterations in gastrointes-
tinal (GI) transit and digestion; and in adverse effects
on quality of life. Diarrhea is also associated with an
increased risk of infectious complications in patients
with chemotherapy-induced neutropenia.
The onset of CID may also require that the patient’s
dose of the chemotherapy regimen be reduced or dis-
continued, with possible adverse effects on patient
outcome, particularly in the curative adjuvant setting.
In a retrospective analysis of 100 consecutively treated
colorectal cancer patients with diarrhea, 45% of the
673 chemotherapy cycles were associated with CID.
Overall, 52 of 100 patients experienced severe diar-
rhea (grade 3 or 4), and 56 patients required a modifi-
cation in chemotherapeutic regimen (dose reduction,
delay in therapy, or discontinuation) 19. One third of
patients in that series required treatment other than oral
antidiarrheal medications, 23% required hospitaliza-
tion, and 21% received intravenous fluids. Similarly,
Petrelli et al. 20,21 reported that more than 40% of sub-
jects on a regimen of 5-FU with high-dose leucovorin
(LV) developed diarrhea, and 52% of those patients
required a reduction of their chemotherapy dose.
A Canadian Working Group retrospective analy-
sis of 63 colorectal cancer patients requiring hospi-
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talization after receiving a variety of chemotherapy
regimens with or without concurrent radiotherapy
found that 58% developed severe diarrhea after the
first cycle of chemotherapy and that 59.6% required
a reduction of, change in, or discontinuation of their
chemotherapy regimen (Table II) 22. An analysis of
two trials sponsored by the U.S. National Cancer In-
stitute (NCI) reported that CID may be associated with
a substantially increased risk of early mortality among
patients treated with the Saltz regimen 23 of irinotecan/
bolus 5-FU/LV (IFL) 24. In the North Central Cancer
Treatment Group trial N9741, involving patients with
advanced metastatic colorectal cancer, the rate of
treatment-induced or treatment-exacerbated mortal-
ity with the IFL regimen (10 of 289 patients—3.5%)
was three times that seen with the oxaliplatin plus
5-FU/LV (3 of 277 patients—1.1%) or oxaliplatin plus
irinotecan (3 of 277—1.1%) regimens.
In the Cancer and Leukemia Group B adjuvant
treatment trial C89803, mortality was 2.5% with the
IFL regimen and 0.8% with bolus weekly 5-FU/LV. An
independent review panel concluded that most of the
deaths could be attributed to GI toxicity and cardiovas-
cular events 24. The GI toxicity deaths were attributable
TABLE I Incidence of diarrhea caused by chemotherapeutic agents in colorectal cancer
Agent Diarrhea Incidence
grade (%)
Intravenous 5-FU + intravenous LV 1 1 or 2 38
5-FU intravenous push 2 3 or 4 12
5-FU intravenous push + intravenous LV 2 All 83
3 or 4 37
5-FU intravenous push + high-dose LV 2 3 or 4 27
Continuous infusion 5-FU 2 3 or 4 6
Continuous infusion 5-FU + low-dose LV 2 3 or 4 11
5-FU 24-hour infusion 2 3 or 4 11
Intravenous 5-FU (high dose) + oral LV 3 32 6
41
Oral TG + oral LV 4 33 1
Irinotecan intravenous infusion vs. supportive care 5 3 or 4 22
3 or 4 6
Intravenous paclitaxel 6 3 or 4 17
Continuous infusion 5-FU 7 vs. intravenous irinotecan 7 3 or 4 11
3 or 4 22
Intravenous irinotecan 8 All 82
3 or 4 32
Intravenous irinotecan + intravenous oxaliplatin 9 3 or 4 19
Intravenous irinotecan + intravenous 5-FU + intravenous LV 10 3 or 4 24
Irinotecan + L-folinic acid + intravenous LV + bolus 5-FU + continuous infusion 5-FU (FOLFIRI) 11,12 3 or 4 11
Oxaliplatin + bolus 5-FU + continuous infusion 5-FU + intravenous LV (FOLFOX) 11,13 3 or 4 11
FOLFOX + bevacizumab 14 3 or 4 11
High-dose continuous infusion 5-FU + intravenous LV + oxaliplatin (FLOX) 15 All 66
3 or 4 29
Oxaliplatin + capecitabine + bevacizumab 16 All 73
3 or 4 30
Irinotecan + bolus 5-FU + LV + bevacizumab 17 3 or 4 32
Adapted, with permission, from Evaluation and Management Guidelines for the Treatment of Chemotherapy-Induced Diarrhea: A Primer.
Chicago: Robert H. Lurie Comprehensive Cancer Center of Northwestern University; 1999.
5-FU = 5-fluorouracil; LV = leucovorin; TG = tegafur.
TABLE II Clinical and therapeutic sequelae of grades 3 and 4 diar-
rhea in a retrospective analysis of 63 colorectal cancer patients who
were hospitalized for supportive care
Parameter Prevalence (%)
Grade 3 or 4 CID 58
Required dose reduction 9.5
Required change in regimen 15.9
Discontinued chemotherapy 34.2
Events associated with CID
Cramping 39.7
Bloody stools 9.5
Uncontrolled emesis 20.6
Fever requiring antibiotic support 30.2
Stomatitis 7.9
Neutropenia 59.7
Febrile neutropenia 39.7
Mortality 4.8 a
Required additional clinic visit 58.7
Required emergency department visit 42.9
Adapted, with permission, from reference 22.
a Uncontrolled diarrhea may have contributed to 3 of 9 deaths in
this series.
CID = chemotherapy-induced diarrhea.MANAGEMENT OF DIARRHEA
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mostly to a syndrome comprising severe diarrhea, nau-
sea and vomiting, anorexia, and abdominal cramping.
Associated features included severe dehydration, neu-
tropenia, fever, and electrolyte imbalances.
A further consideration is the cost of CID man-
agement. In a retrospective analysis by Dranitsaris
et al. 22 of a Canadian cohort of patients with
colorectal cancer who had undergone chemotherapy
and required hospital admission after the occurrence
of grade 3 or 4 CID, the median stay was 8 days. Of
63 patients, 55 (87.3%) required parenteral support,
and 50 (79.3%) received intravenous or oral antibi-
otics. There were 9 deaths recorded (14.3%). The
median time to resolution of CID was 12 days. The
estimated cost impact of CID was CA$8230 per pa-
tient, of which CA$6314 (76.7%) was for hospital-
ization. That cost exceeds the estimated cost of other
toxic events associated with chemotherapy that re-
quire hospitalization, such as the cost of febrile neu-
tropenia (CA$5871) and cardiotoxicity (CA$4626)
in breast cancer patients (2004 Canadian dollars) 25.
The significant morbidity and mortality associ-
ated with CID have demonstrated the need for a more
comprehensive assessment of diarrhea and a more
aggressive and systematic treatment approach. The
Canadian Working Group on Chemotherapy-Induced
Diarrhea was formed to address the need for more
effective detection and management of CID. The
Group’s consensus recommendations on the preven-
tion and management of CID follow. These recom-
mendations expand upon guidelines previously
developed by Wadler et al. 26,27 and by Cancer Care
Ontario 28, and they address the potential use of an-
tidiarrheal prophylaxis in high-risk patients. Where
level 1 evidence was lacking, the recommendations
were based on expert clinical opinion.
2. CONSENSUS STATEMENT
2.1 Grading of CID
Recommendation: The severity of CID should be
evaluated using the current NCI criteria (Table III) 29.
However, because the NCI criteria do not provide a
complete assessment of diarrhea, additional informa-
tion (duration of the diarrhea episode, stool charac-
teristics, and coexisting symptoms) should be
obtained during the patient evaluation. In view of the
importance of CID in many modern chemotherapeu-
tic regimens used in colorectal cancer, it might be
appropriate to modify the NCI criteria, taking the above
points in consideration, to provide a more relevant
diarrhea grading.
2.2 Identification of CID Risk Factors
Few studies have attempted to identify risk factors
for the development of CID. Cascinu et al. 30 reported
that the presence of a primary tumour, past history of
CID, and chemotherapy administered during the sum-
mer months were possible risk factors. Other studies
have indicated that patient age (older > younger) and
sex (female > male) are additional risk factors 31,32.
The Canadian Working Group is currently con-
ducting a retrospective multicentre case analysis of
319 patients with colorectal cancer. According to the
preliminary multivariate analysis, resection of the
primary tumour in the bowel and irinotecan chemo-
therapy are significant risk factors for CID 33. Patients
treated in an adjuvant (as opposed to metastatic) set-
ting are also at greater risk of severe CID.
The Working Group is using these data to de-
velop a model for predicting the patients that are at
greater risk of severe diarrhea 33. Important variables
in the predictive index include the first cycle of che-
motherapy (as opposed to later cycles, during which
the CID risk declines), a cycle duration greater than
3 weeks, coexisting neutropenia, and the presence
of concomitant symptoms (stomatitis, emesis, anor-
exia, anemia, cramps, or a combination of these).
The development of grade 1 or 2 CID following the
first cycle was seen as protective for future severe
events—likely because of the initiation of more in-
tensive early monitoring.
2.2.1 Future Directions
The preliminary model requires external validation
before a predictive index can be implemented in clini-
cal practice. Nevertheless, a predictive model would
be invaluable in optimizing cancer therapy.
In addition to the clinical assessment of risk fac-
tors, genetic changes at the molecular level might be
evaluated to identify the risk of toxicities with che-
motherapeutic agents. The two main examples of in-
TABLE III National Cancer Institute criteria for severity of chemo-
therapy-induced diarrhea
Toxicity grade Criteria
1 Increase of <4 stools daily over baseline
Mild increase in ostomy output as compared
with baseline
2 Increase of 4–6 stools daily over baseline
Intravenous fluids indicated <24 hours
Moderate increase in ostomy output compared
with baseline
Not interfering with activities of daily living
3 Increase of ³7 stools daily over baseline
Incontinence; intravenous fluids >24 hours
Hospitalization
Severe increase in ostomy output compared
with baseline
Interfering with activities of daily living
4 Life-threatening consequences (for example,
hemodynamic collapse)
5 Death
Adapted, with permission, from reference 29.MAROUN et al.
16
CURRENT ONCOLOGY—VOLUME 14, NUMBER 1
terest in the treatment of colorectal cancer relate to
5-FU and irinotecan:
• Dihydropyrimidine dehydrogenase (DPD) plays a
central role in 5-FU metabolism, and DPD defi-
ciency is well documented as possibly resulting
in severe 5-FU–associated toxicity 34.
• The morbidity associated with irinotecan chemo-
therapy may also be reduced by screening can-
didates for uridine diphosphate glucuronyl
transferase (UGT) polymorphisms. Polymor-
phisms in this enzyme affect glucuronidation of
the irinotecan metabolite SN-38. One study re-
ported that the incidence of grades 3 and 4 diar-
rhea is 70% in subjects with seven repeats (TA7)
in the UGT1A1 isoenzyme promoter region, as
compared with 15% in patients with normal al-
leles 35. The TA7 genotype is also associated with
an increased risk of neutropenia 35,36. While not
routinely performed at present, testing for DPD
levels and UGT1A1 may soon become more
widely available for patients receiving 5-FU or
irinotecan. The U.S. package insert for irinotecan
now recommends a lower starting dose for pa-
tients known to be homozygous for the
UGT1A1*28 polymorphism 37.
2.3 Investigations
Recommendation: Patients should be evaluated for
possible causes of diarrhea such as medications (for
example, laxatives, stool softeners, antacids, antibi-
otics) and diet (for example, fibre, lactose), comor-
bid infection, partial intestinal obstruction or fecal
impaction, surgery (for example, post-gastrectomy,
short-bowel syndrome), and acute or chronic radia-
tion toxicity.
Recommendation: The recommended laboratory in-
vestigations include a complete blood count and dif-
ferential to rule out neutropenia; blood chemistry to
determine the presence of electrolyte abnormalities
and to assess renal function; and stool analyses in cases
of persistent diarrhea to identify possible bacterial
(Clostridium difficile, C. perfringens, Salmonella spe-
cies, Shigella species), fungal (Candida), parasitic
(Giardia) or viral (rotavirus) pathogens. Other inves-
tigations may be warranted, such as abdominal X-ray
to rule out coexisting disorders (bowel obstruction,
perforation) and endoscopy or biopsy where indicated.
2.4 Patient Management: Acute Setting
The development of CID requires prompt, effective
intervention. The general management of CID may
include bowel rest, hydration, and replacement of
electrolytes. Hospitalization is required for patients
with dehydration, fever, neutropenia, or nausea and
vomiting that prevents adequate oral hydration.
Patients should be advised to modify their diet to
eliminate substances that may contribute to diarrhea
(for example, milk and high-fat foods) and should be
instructed to avoid caffeinated beverages and alco-
hol 38. Patients should be advised to increase their
intake of oral fluids suitable for rehydration.
The conventional first-line treatments for CID are
the opioids loperamide and diphenoxylate. Double-
blind trials indicate that loperamide is the more ef-
fective agent of the two for acute diarrhea 39–41. The
recommended standard dose of loperamide is 4 mg
initially, followed by 2 mg with every episode of di-
arrhea to a maximum of 16 mg daily 42,43. High-dose
loperamide (4 mg initially, followed by 2 mg every
2 hours) appears to be moderately effective in irino-
tecan-induced diarrhea 44,45. The maximum dose for
irinotecan-induced diarrhea is 24 mg daily (Figure 1).
For intractable grade 1 or 2 diarrhea or de novo
grade 3 or 4 diarrhea, the somatostatin analogue
octreotide is the recommended treatment. In clinical
trials, octreotide 100–150 mg subcutaneously three
times daily has been shown to be effective in resolv-
ing grades 3 and 4 diarrhea in 60%–95% of patients
after chemotherapy 46–48 or pelvic radiotherapy 49. A
higher octreotide dose (500 mg subcutaneously three
times daily) has been shown to be well-tolerated 50
FIGURE 1 Acute management of grades 1 and 2 diarrhea. SC =
subcutaneously; TID = three times daily.MANAGEMENT OF DIARRHEA
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and more effective in resolving intractable diarrhea
in chemotherapy patients 48. The increased cost of the
higher dose may be justified by the reduction in hos-
pitalization time, but this hypothesis requires further
study.
Recommendation: Patients developing diarrhea
should be treated with standard doses of loperamide.
A higher dose may be employed for mild-to-moder-
ate diarrhea (grade 1 or 2) that persists for more than
24 hours. Loperamide should be discontinued
12 hours after diarrhea resolves and a normal diet has
been re-established.
Recommendation: Hospitalization should be consid-
ered for patients with grade 2 diarrhea that does not
resolve after 24 hours of high-dose loperamide, par-
ticularly if they show evidence of clinical deteriora-
tion. Hospitalization is recommended for all patients
with severe diarrhea (grades 3 and 4; Figure 2). Pa-
tients managed in hospital should receive intravenous
fluids for correction of dehydration and electrolyte
abnormalities as needed, and antibiotics (for example,
fluoroquinolone).
Recommendation: Grade 2 diarrhea refractory to
high-dose loperamide should be treated with
octreotide 100–150 mg subcutaneously three times
daily. Octreotide may be considered for patients with
grade 1 diarrhea that is refractory to high-dose
loperamide. Following octreotide initiation, loper-
amide dosing may be maintained or discontinued.
Recommendation: For patients with severe (grades 3
and 4) diarrhea, octreotide 100–150 mg subcutane-
ously three times daily is the recommended first-line
agent. The dose may be escalated if the patient does
not respond within 24 hours. Patients should receive
intravenous fluids and electrolytes as needed and
antibiotics (for example, fluoroquinolone).
Current guidelines recommend increasing the
dose of octreotide in 50-mg increments in patients
who do not adequately respond 27, but the Working
Group recommends dose escalation to octreotide
300–500 mg subcutaneously three times daily until
diarrhea resolves 48. This latter recommendation is
based on clinical practice rather than on published
trial data. Octreotide should be discontinued 24 hours
after the diarrhea has resolved and a normal diet has
been re-established.
2.5 Patient Management: Prophylaxis
Adjuvant therapy for colorectal cancer poses special
challenges, because the intent is curative, and a re-
duction or delay in the chemotherapy regimen be-
cause of severe diarrhea may compromise the
outcome of treatment.
Current guidelines express the need for diarrhea
prophylaxis, but offer no recommendations. In a pre-
liminary study 51, octreotide 150 mg three times daily
administered in conjunction with 5-FU/LV in adult
cancer patients was not generally effective. Of 10 pa-
tients undergoing treatment, 2 experienced dose-lim-
iting diarrhea. Only 3 patients were able to tolerate
6 weekly chemotherapy treatments without a dose
reduction or delay.
A long-acting, slow-release (LAR) formulation of
octreotide was effective in a small case series of 9 pa-
tients with colorectal cancer who developed severe
refractory diarrhea after fluoropyrimidine or
irinotecan chemotherapy 52,53. All these patients had
previously failed to respond to antidiarrheal therapy
with loperamide or diphenoxylate, or both. Diarrhea
resolved with once-monthly intramuscular injections
of octreotide LAR 30 mg, and no further hospitaliza-
tions for CID were required. The optimal dose of
octreotide LAR has not been established. The
Sandostatin  LAR Trial for the Optimum Prevention of
CID is currently evaluating the efficacy of octreotide
LAR 30 mg as compared with 40 mg in patients with
severe CID.
Currently, no completed large randomized con-
trolled trials have addressed the issue of prophylaxis.
(Ongoing trials are discussed at the end of this sub-
section.) The recommendations that follow are in-
terim suggestions based on the above-cited case series
and the expert opinion of the Working Group. Fur-
ther study is warranted.
Recommendation: Octreotide LAR 30 mg intramus-
cularly every 28 days may be considered for patients
with colorectal cancer who have experienced grade 3
or 4 diarrhea in a previous chemotherapy cycle and
who require another course of chemotherapy, par-
ticularly if dose reduction is not desirable (for ex-
ample, in the adjuvant and neoadjuvant settings;
Figure 3).
Recommendation: For de novo patients with rectal
cancer who are undergoing concurrent adjuvant che-
motherapy and radiotherapy, no clinical trials have
FIGURE 2 Acute management of grades 3 and 4 diarrhea. CID =
chemotherapy-induced diarrhea; SC = subcutaneously; TID = three
times daily.MAROUN et al.
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been completed. Octreotide LAR 30 mg intramuscu-
larly may be a treatment option in this setting.
The extent of benefit on CID prophylaxis and pa-
tient quality of life is not currently known, but is now
being investigated in a Canadian multicentre phase III
randomized study of octreotide LAR prophylaxis
(monthly for 6 months, starting 2 weeks before the
first dose of chemotherapy) in patients with rectal
cancer treated with postoperative 5-FU and radiation
in an adjuvant setting. Octreotide LAR is also being
evaluated in a phase III randomized double-blind trial
of 226 patients receiving chemoradiotherapy for anal
or rectal cancer (RTOG-0315) 54. Subjects will receive
an octreotide LAR or placebo injection 4–7 days be-
fore chemoradiotherapy and on day 22 of treatment.
3. CONCLUSION
Chemotherapy-induced diarrhea is a severe and fre-
quently undertreated side effect of cancer therapy that
requires prompt and effective management to pre-
vent complications, maintain the chemotherapeutic
regimen, and improve patient quality of life. A sys-
tematic approach to the management of CID is impor-
tant. Aggressive management with high-dose
loperamide or subcutaneous octreotide—and prophy-
laxis with the intramuscular LAR formulation of
octreotide—may reduce the morbidity and mortality
associated with CID and improve patient outcomes.
Many of the preceding recommendations were
perforce based on clinical observation rather than
on randomized trials, highlighting the need for more
research on the causes of CID and on its optimal man-
agement. As part of that effort, the Canadian Work-
ing Group is continuing to analyze its colorectal
cancer database and available information on ge-
netic changes predisposing to toxicity with chemo-
radiation regimens to identify possible risk factors,
and is completing additional validation work on its
predictive model. When the model is complete, the
Working Group hopes that it will enable clinicians
to identify patients at highest risk of developing CID
so that effective and cost-effective prophylactic
measures can be instituted. The ongoing Canadian
randomized trial of CID prophylaxis in rectal cancer
patients receiving adjuvant chemoradiation will pro-
vide further information on the role of LAR octreotide
in CID prophylaxis.
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